China’s Changchun New Area Introduces Exit-Entry Policies for Overseas Talent
Seven exit and entry policies and measures were approved Tuesday to attract foreign talents to Changchun New Area in northeast China’s Jilin Province.
The policies make it easier for talents to enter and exit the new area, and provide favorable terms to acquire permanent residence.
For foreign talents, spouses and under aged children that conform to the accreditation criteria, they can apply for permanent residence when recommended by the area’s administrative committee.
For foreign nationals living in the new area for a required period and with income and tax payment in line with the standards of the new policies, they can apply for permanent residence, and their spouses and under aged children can apply along with them.
For overseas Chinese working in the new area, those with a doctoral degree or those living in the area for a required period can apply for the permanent residence.
Foreign students also enjoy favorable terms to work and live in the new area.
And foreign nationals, who work in the new area and have no violation of laws and regulations, can have the validity period of their work-related residence permit extended to five years when they apply it for the third time.
The Changchun New Area is one of China's national-level new areas and an important engine to rejuvenate the country’s northeast.
The new area has gathered quite a number of foreign-funded enterprises and the new policies aim to draw talents to meet its increasing demand for high-caliber professionals.
Changchun New Area Commission
Ms. Lina Wang, +86 137 5628 1088
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DE-INCYTE21.10.2018 12:47 | pressemeddelelse
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
SERVIER21.10.2018 11:12 | pressemeddelelse
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum